In October 2026 the CHMP confirmed its refusal of Yartemlea (narsoplimab) following re-examination. The case is a useful reminder of how the re-examination procedure works and when it is worth using.
The procedure in outline
Under Regulation (EC) No 726/2004, an applicant may request re-examination of a negative opinion. The request is made in writing within 15 days of receiving the opinion, and the detailed grounds follow within 60 days. The CHMP then re-examines the opinion, normally within 60 days of receiving the grounds, and a different rapporteur and co-rapporteur are appointed.
What the Committee can and cannot consider
Re-examination is a review of the original opinion against the grounds submitted. It is not an opportunity to submit a new dossier. Argument must engage with the specific objections recorded, and new data are generally not a route to reversal. An ad hoc expert group or an oral explanation may be part of the process.
Deciding whether to request it
- Are the grounds addressable? Disagreement about interpretation of existing data is a different position from missing data.
- Is a new application a better route? Sometimes generating further evidence and resubmitting is more realistic than contesting the opinion.
- What is the communication plan? A negative opinion is published, so investors, partners and clinicians need consistent messaging.
Learning from earlier steps
Most negative opinions can be anticipated. Scientific advice, a frank reading of the list of outstanding issues and a realistic assessment of the pivotal evidence reduce the chance of ever reaching this stage.
How PQRA helps
PQRA helps sponsors prepare for oral explanations, structure responses to outstanding issues, and decide between re-examination and resubmission, with the regulatory and commercial consequences mapped out beforehand.


No responses yet